Methotrexate for rheumatoid arthritis
96 results
1 - 96Methotrexate for rheumatoid arthritis
Methotrexate for treating rheumatoid arthritis
Biologics for people with rheumatoid arthritis naive to methotrexate
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta‐analysis
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis): Cochrane systematic review
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
Rheumatoid arthritis
Rituximab for rheumatoid arthritis: Cochrane systematic review
Adalimumab for treating rheumatoid arthritis
Infliximab for the treatment of rheumatoid arthritis
Juvenile idiopathic arthritis (juvenile rheumatoid arthritis)
Combination therapy in rheumatoid arthritis
Adding MTX to sulfasalazine better for RA (MASCOT)
Penicillamine for treating rheumatoid arthritis
Psoriatic arthritis
Adalimumab for treating rheumatoid arthritis
Golimumab for rheumatoid arthritis: Cochrane systematic review
Rituximab for rheumatoid arthritis
Golimumab for rheumatoid arthritis
MTX associated with decreased CVD risk in patients with RA
Methotrexate for psoriatic arthritis
Tocilizumab for rheumatoid arthritis: Cochrane systematic review
Tocilizumab for rheumatoid arthritis
Fish oil in rheumatoid arthritis
2010 classification criteria for rheumatoid arthritis
Guidelines: Management of RA
Iritis (inflammation of the iris)
Etanercept for the treatment of rheumatoid arthritis: Cochrane systematic review
Infections in immunosuppressed and cancer patients
Infliximab for rheumatoid arthritis
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Methotrexate for psoriatic arthritis
RA options: MTX still first-line
Certolizumab pegol for rheumatoid arthritis in adults
Auranofin versus placebo in rheumatoid arthritis
Anakinra for rheumatoid arthritis
Cyclophosphamide for treating rheumatoid arthritis
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
Updated ACR guideline on managing patients with rheumatoid arthritis
Pleural effusions and thoracentesis
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics
Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis): Cochrane systematic review
Leflunomide for the treatment of rheumatoid arthritis
EULAR/ACR guideline on managing patients with polymyalgia rheumatica
Methotrexate for induction of remission in refractory Crohn's disease: Cochrane systematic review
Etanercept for the treatment of rheumatoid arthritis
Methotrexate for ankylosing spondylitis
Chronic diseases and pregnancy
Antidepressants for pain management in rheumatoid arthritis: Cochrane systematic review
Prolonged cough in adults
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)